Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabidiol

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RespRx

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undiaclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 23, 2020

            Details:

            The master services agreement with a clinical research organization in the U.S. will support PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nomacopan

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            Following initial proof of principle study in Brazil and subsequent Data and Safety Monitoring Board (DSMB) review, a double blind randomized clinical study with nomacopan is recruiting patients in Brazil.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 4D-710

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: 4D-710

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation

            Deal Size: $14.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement June 17, 2020

            Details:

            Under this agreement, the CF Foundation will support the completion of IND-enabling research and development activities, and the planned Phase 1/2 clinical study of 4D-710, 4DMT’s wholly-owned product candidate for the aerosol treatment of CF lung disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALT-100

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 27, 2020

            Details:

            Aqualung has begun IND-enabling pharmaco-dynamic, pharmacokinetic and toxicology studies that will advance their lead therapeutic ALT-100 into human studies to treat Acute Respiratory Distress Syndrome (ARDS).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-100

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Airway Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 20, 2020

            Details:

            Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Grapiprant

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 02, 2020

            Details:

            COVID-19 IND has been opened with the FDA for AT-001, in global Phase 3 development for Diabetic Cardiomyopathy. Multiple AT-001 investigator-initiated trials are now underway.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALT-100

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2020

            Details:

            Aqualung Therapeutics Corporation is developing ALT-100 to reduce the mortality of Acute Respiratory Distress Syndrome (ARDS) and Ventilator-Induced Lung Injury (VILI).